Development of a portable hypoxia chamber for ultra-high dose rate laser-driven proton radiobiology applications.
DNA repair
Hypoxia
Laser-driven protons
Ultra-high dose rate
Journal
Radiation oncology (London, England)
ISSN: 1748-717X
Titre abrégé: Radiat Oncol
Pays: England
ID NLM: 101265111
Informations de publication
Date de publication:
15 Apr 2022
15 Apr 2022
Historique:
received:
29
06
2021
accepted:
03
03
2022
entrez:
16
4
2022
pubmed:
17
4
2022
medline:
20
4
2022
Statut:
epublish
Résumé
There is currently significant interest in assessing the role of oxygen in the radiobiological effects at ultra-high dose rates. Oxygen modulation is postulated to play a role in the enhanced sparing effect observed in FLASH radiotherapy, where particles are delivered at 40-1000 Gy/s. Furthermore, the development of laser-driven accelerators now enables radiobiology experiments in extreme regimes where dose rates can exceed 10 We used oxygen concentration measurements to test the induction of hypoxia and the maintenance capacity of the chambers. Cellular hypoxia induction was verified using hypoxia inducible factor-1α immunostaining. Calibrated radiochromic films and GEANT-4 simulations verified the dosimetry variations inside and outside the chambers. We irradiated hypoxic human skin fibroblasts (AG01522B) cells with laser-driven protons, conventional protons and reference 225 kVp X-rays to quantify DNA DSB damage and repair under hypoxia. We further measured the oxygen enhancement ratio for cell survival after X-ray exposure in normal fibroblast and radioresistant patient- derived GBM stem cells. Oxygen measurements showed that our chambers maintained a radiobiological hypoxic environment for at least 45 min and pathological hypoxia for up to 24 h after disconnecting the chambers from the gas supply. We observed a significant reduction in the 53BP1 foci induced by laser-driven protons, conventional protons and X-rays in the hypoxic cells compared to normoxic cells at 30 min post-irradiation. Under hypoxic irradiations, the Laser-driven protons induced significant residual DNA DSB damage in hypoxic AG01522B cells compared to the conventional dose rate protons suggesting an important impact of these extremely high dose-rate exposures. We obtained an oxygen enhancement ratio (OER) of 2.1 ± 0.1 and 2.5 ± 0.1 respectively for the AG01522B and patient-derived GBM stem cells for X-ray irradiation using our hypoxia chambers. We demonstrated the design and application of portable hypoxia chambers for studying cellular radiobiological endpoints after exposure to laser-driven protons at ultra-high dose, conventional protons and X-rays. Suitable levels of reduced oxygen concentration could be maintained in the absence of external gassing to quantify hypoxic effects. The data obtained provided indication of an enhanced residual DNA DSB damage under hypoxic conditions at ultra-high dose rate compared to the conventional protons or X-rays.
Sections du résumé
BACKGROUND
BACKGROUND
There is currently significant interest in assessing the role of oxygen in the radiobiological effects at ultra-high dose rates. Oxygen modulation is postulated to play a role in the enhanced sparing effect observed in FLASH radiotherapy, where particles are delivered at 40-1000 Gy/s. Furthermore, the development of laser-driven accelerators now enables radiobiology experiments in extreme regimes where dose rates can exceed 10
MATERIALS AND METHODS
METHODS
We used oxygen concentration measurements to test the induction of hypoxia and the maintenance capacity of the chambers. Cellular hypoxia induction was verified using hypoxia inducible factor-1α immunostaining. Calibrated radiochromic films and GEANT-4 simulations verified the dosimetry variations inside and outside the chambers. We irradiated hypoxic human skin fibroblasts (AG01522B) cells with laser-driven protons, conventional protons and reference 225 kVp X-rays to quantify DNA DSB damage and repair under hypoxia. We further measured the oxygen enhancement ratio for cell survival after X-ray exposure in normal fibroblast and radioresistant patient- derived GBM stem cells.
RESULTS
RESULTS
Oxygen measurements showed that our chambers maintained a radiobiological hypoxic environment for at least 45 min and pathological hypoxia for up to 24 h after disconnecting the chambers from the gas supply. We observed a significant reduction in the 53BP1 foci induced by laser-driven protons, conventional protons and X-rays in the hypoxic cells compared to normoxic cells at 30 min post-irradiation. Under hypoxic irradiations, the Laser-driven protons induced significant residual DNA DSB damage in hypoxic AG01522B cells compared to the conventional dose rate protons suggesting an important impact of these extremely high dose-rate exposures. We obtained an oxygen enhancement ratio (OER) of 2.1 ± 0.1 and 2.5 ± 0.1 respectively for the AG01522B and patient-derived GBM stem cells for X-ray irradiation using our hypoxia chambers.
CONCLUSION
CONCLUSIONS
We demonstrated the design and application of portable hypoxia chambers for studying cellular radiobiological endpoints after exposure to laser-driven protons at ultra-high dose, conventional protons and X-rays. Suitable levels of reduced oxygen concentration could be maintained in the absence of external gassing to quantify hypoxic effects. The data obtained provided indication of an enhanced residual DNA DSB damage under hypoxic conditions at ultra-high dose rate compared to the conventional protons or X-rays.
Identifiants
pubmed: 35428301
doi: 10.1186/s13014-022-02024-3
pii: 10.1186/s13014-022-02024-3
pmc: PMC9013042
doi:
Substances chimiques
Protons
0
DNA
9007-49-2
Oxygen
S88TT14065
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
77Subventions
Organisme : engineering and physical sciences research council
ID : EP/K022415/1
Organisme : engineering and physical sciences research council
ID : EPJ500094/1
Organisme : engineering and physical sciences research council
ID : EP/P010059/1
Organisme : european metrology programme for innovation and research
ID : 18HLT04 UHD
Organisme : horizon 2020 framework programme
ID : European Union's Horizon 2020 research
Organisme : horizon 2020 framework programme
ID : innovation program under the Marie Sklowdowska-Curie grant agreement no 754507
Informations de copyright
© 2022. The Author(s).
Références
Semin Nucl Med. 2020 Nov;50(6):562-583
pubmed: 33059825
Am J Cancer Res. 2014 Jan 15;4(1):53-60
pubmed: 24482738
Biochem Biophys Res Commun. 2012 May 18;421(4):855-9
pubmed: 22554525
Sci Rep. 2016 Aug 31;6:32441
pubmed: 27578260
Cancer Res. 2015 Oct 15;75(20):4416-28
pubmed: 26282173
Med Phys. 2020 Dec;47(12):6551-6561
pubmed: 33089504
Int J Cancer. 2011 Dec 15;129(12):2928-34
pubmed: 21491423
Adv Drug Deliv Rev. 2017 Jan 15;109:26-44
pubmed: 27919760
Int J Radiat Biol Relat Stud Phys Chem Med. 1974 Jul;26(1):17-29
pubmed: 4607987
Clin Oncol (R Coll Radiol). 2003 Feb;15(1):S10-5
pubmed: 12602558
Radiat Oncol. 2018 Nov 13;13(1):220
pubmed: 30424810
Br J Radiol. 2014 Mar;87(1035):20130676
pubmed: 24588669
Int J Oncol. 2008 Dec;33(6):1247-56
pubmed: 19020758
Front Oncol. 2021 Jul 29;11:686142
pubmed: 34395253
Radiat Oncol. 2011 Dec 15;6:171
pubmed: 22172079
Med Phys. 2017 Feb;44(2):725-735
pubmed: 28019660
Phys Med Biol. 2012 Oct 21;57(20):6671-80
pubmed: 23022765
Radiat Res. 2003 Jan;159(1):94-101
pubmed: 12492372
Proc Natl Acad Sci U S A. 2011 May 17;108(20):8293-8
pubmed: 21527720
Int J Radiat Oncol Biol Phys. 2020 Jul 1;107(3):539-547
pubmed: 32145319
J Radiat Res. 2014 Sep;55(5):1028-32
pubmed: 24876271
Br J Radiol. 1953 Dec;26(312):638-48
pubmed: 13106296
Cancers (Basel). 2021 Jun 15;13(12):
pubmed: 34203882
Sci Transl Med. 2014 Jul 16;6(245):245ra93
pubmed: 25031268
Sci Rep. 2015 Nov 24;5:17016
pubmed: 26596243
Int J Radiat Oncol Biol Phys. 2016 May 1;95(1):86-94
pubmed: 26452569
Nucleic Acids Res. 2009 Jul;37(12):3912-23
pubmed: 19401436
J Radiat Res. 2013 Jul;54 Suppl 1:i23-30
pubmed: 23824123
J Radiat Res. 2014 Sep;55(5):902-11
pubmed: 24728013
Int J Radiat Biol. 1990 Aug;58(2):261-77
pubmed: 1974574
Radiother Oncol. 2019 Oct;139:51-55
pubmed: 30850209
Radiat Res. 1991 Sep;127(3):297-307
pubmed: 1886986
Proc Natl Acad Sci U S A. 2019 May 28;116(22):10943-10951
pubmed: 31097580
Sci Rep. 2019 Mar 14;9(1):4471
pubmed: 30872656
Phys Rev Lett. 2000 Oct 2;85(14):2945-8
pubmed: 11005974
Br J Radiol. 2019 Jan;92(1093):20180008
pubmed: 29694234
Radiother Oncol. 2019 Oct;139:18-22
pubmed: 31303340
Br J Radiol. 2018 Feb;91(1082):20170628
pubmed: 29172684
Int J Radiat Oncol Biol Phys. 2016 May 1;95(1):70-77
pubmed: 27084630
Br J Radiol. 2020 Feb 01;93(1106):20190702
pubmed: 31825653
Med Phys. 2021 Jul;48(7):3982-3990
pubmed: 33948958
J Cancer Res Clin Oncol. 2020 Jan;146(1):19-31
pubmed: 31734836
Neuro Oncol. 2017 Feb 1;19(2):229-241
pubmed: 27576873
J Radiat Res. 2005 Sep;46(3):325-32
pubmed: 16210789
Int J Radiat Oncol Biol Phys. 2021 Jul 1;110(3):833-844
pubmed: 33545301
Int J Radiat Oncol Biol Phys. 2014 Sep 1;90(1):27-35
pubmed: 24986743
Radiother Oncol. 2017 Sep;124(3):365-369
pubmed: 28545957
Proc Natl Acad Sci U S A. 2012 Jan 10;109(2):443-8
pubmed: 22184222
J Radiat Res. 2013 Jul;54 Suppl 1:i13-22
pubmed: 23824117
Acta Oncol. 2015;54(9):1614-22
pubmed: 26198655
Radiother Oncol. 2021 Sep;162:68-75
pubmed: 34214612
Clin Cancer Res. 2019 Jan 1;25(1):35-42
pubmed: 29875213
Nat Rev Mol Cell Biol. 2014 Jan;15(1):7-18
pubmed: 24326623
J Cell Sci. 2012 Jan 1;125(Pt 1):189-99
pubmed: 22266907
Clin Cancer Res. 2006 Apr 1;12(7 Pt 1):2185-90
pubmed: 16609033
Radiat Res. 2017 Dec;188(6):636-644
pubmed: 29019742
Mol Oncol. 2015 Jan;9(1):192-203
pubmed: 25205037
Cancers (Basel). 2020 Jun 24;12(6):
pubmed: 32599789
Med Phys. 2022 Mar;49(3):2068-2081
pubmed: 34407219
Med Phys. 2012 May;39(5):2447-55
pubmed: 22559615
Trends Cell Biol. 2014 Feb;24(2):108-17
pubmed: 24094932
Acta Oncol. 2013 Nov;52(8):1723-9
pubmed: 23317145
Phys Med Biol. 2011 Jun 7;56(11):3251-68
pubmed: 21540489
Int J Radiat Oncol Biol Phys. 2020 Feb 1;106(2):440-448
pubmed: 31928642
Acta Oncol. 2010 Oct;49(7):1170-6
pubmed: 20831510
J Pers Med. 2021 Apr 16;11(4):
pubmed: 33923454